PUBLISHER: Grand View Research | PRODUCT CODE: 1511833
PUBLISHER: Grand View Research | PRODUCT CODE: 1511833
The global latent tuberculosis infection detection market size is expected to reach USD 2.63 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.44% from 2024 to 2030. The increased risk of developing active disease from latent tuberculosis infection (LTBI) coupled with the surge in the geriatric population globally is one of the major driving factors for the market growth. In addition, rising awareness about TB detection and various government initiatives for effective diagnosis and screening of tuberculosis infection is another factor contributing to market expansion. For instance, in July 2021, the UKHSA and NHS of England launched a 5-year plan to decrease TB cases in the country.
The market growth is fueled by the increase in the geriatric population across the globe. For instance, according to the elderly population report of America's Health Rankings 2021, more than 54 million population aged more than 65 years in the U.S. which accounts for 16.5% of the country's population. The geriatric population is highly susceptible to developing latent TB infection. Policymakers and public health officials are making improvements in policies to improve the health of older in the country.
Furthermore, ongoing funding activities by leading organizations to promote the diagnosis and testing for tuberculosis are also expected to fuel market growth. For instance, Unitaid is a leading health agency engaged in discovering quick solutions for diseases. In September 2022, the Unitaid launched funding of USD 30 million to boost tuberculosis detection. This funding will support the development of same-day tests and also help in the development of novel diagnostic technologies for tuberculosis.
Similarly, the Global Fund provides support and funding for the management of infectious diseases such as tuberculosis, malaria, and HIV. The organization provides around 76% of global financing for tuberculosis and it has invested around USD 8.5 billion for the management of tuberculosis. Furthermore, in August 2021, the Global Fund provide funds to FIND for the advancement of TB diagnosis and prevention in India. This investment optimized laboratory quality for early diagnosis of TB and improved tuberculosis diagnostic capacity in the country.
In addition, the rising testing efforts globally to promote the diagnosis of TB infection are expected to support market expansion. For instance, in March 2022, QIAGEN N.V. announced that the company has sold 100 million QuantiFERON blood tests since its launch. After this, the company decided to expand QuantiFERON to reach more patients across the globe. Moreover, various strategic initiatives undertaken by leading players to enhance their market share are another factor facilitating market expansion. For instance, in October 2021, QIAGEN announced CE mark approval and roll-out of the QIAreach QuantiFERON-TB test for tuberculosis infection diagnosis.